Dra. Gabriela Nora Cesarman-Maus M.D.

Ponencia: Monitoreo de anticoagulantes de última generación

 

General Information

Date of birth: October 24th 1959

Nationality and Citizenship-Mexican

Medical Licensure- México 1986

Internal Medicine and Sub-Specialty Boards in Hematology/Oncology- México

ECFMG 1989

National Researcher´s System (SIN): level II

 

Educational Background

MD  1986       Universidad Nacional Autonoma de México, (UNAM). Faculty of

Medicine,

SS   1985      Department of Pathology. National Institute of Medical Sciences

(Social Service Thesis: Reclassification of non-Hodgkins

Lymphomas)

MS  1989       Internal Medicine Residency at the National Institute of Medical

Sciences and Nutrition, NIH-Mexico

MSS 1994     Fellowship in Hematology and Oncology at the New York

Hospital –Cornell Medical Center.

  • Post Doctoral Research Fellowship. Vascular Research Center.

Katherine Hajjar’s Laboratory. Cornell Medical Center. Characterization of

Annexin 2. Susan

J Murphy Scholar.

2005-2009     PhD in Ciencias Químico Biológicas at the Instituto Politécnico Nacional

 

 

Professional Positions Held

  • Teachers Assistant, Department of Embriology

1980-1981     Teachers Assistant. Department of Histology

  • Teachers Assistant in Nosology
  • Chief Fellow. Hematology- Oncology Dept. NY Hospital-Cornell

MedicalCenter

1 994 –           Hematology and Oncology Attending at the National Institute of

Medical Sciences and Nutrition , NIH Mexico (INCMNSZ)

1994-            Director, Coagulation Clinical and Research Laboratory. INCMNSZ

  • Head Hemostasis and Thrombosis section for the Mexican Hematology Association (AMEH)

1994 –           Private Practice

2001             Head Scientific Committee for the XVII International Congress

CLAHT (Latin-American  Cooperative Group on Thrombosis and

Hemostasis) Meeting in México City.

  • California Health Advisor for the Mexican Ministry of Foreign Affairs

2003-            Post-Doctoral Research Fellow, Department of Cell and  Developmental

Biology. Weill Medical Center of Cornell University

2007-12        Coordinator for benign Hematology  NCI, Mexico

2007- 2016   Head, Cancer and Thrombosis Service, Department of Hematology , NCI,

Mexico.

2009-12        Coordinator; Catheter and Thrombosis Clinic . NCI, Mexico

2011-13        Scientific Chair.: Asociación Mexicana de Hematología.

2012 –           Tutor Post-graduate Doctorate Program. (Veterinary Medicine, UNAM)

Tutor in Post-graduate Studies for Masters and PhD in Medical Sciences.

National Autonomous University (UNAM).

  1.   Tutor, Facultad de Química, Instituto Politécnico Nacional-

2013-             Representante de FUNSALUD/AMEH

2013-             Professor in Hematology: Faculty of Medicine UNAM (3rd year)

2015-             Research Coordinator, Department of Hematology, NCI.Mexio

2015-             Founding member ¨Sociedad Mexicana de Trombosis y Hemostasia

SOMETH

2016 -2018    Delegate for SOMETH as Board member  of  Thrombosis and Hemostasis

Societies of   North America (THSNA)¨

  1.    Scientific Committee member SOMETH

2015-             Founding member ¨Colegio Mexicano para la Investigación del Cáncer¨

2017              Delegate for CLAHT in Mexico.

 

Professional Thesis Directed

Masters

  • Armando Villegas. UNAM. Masters in Science. Anticoagulant

monitoring in patients with antiphospholipid syndrome.

  • Carlos Cantu. UNAM. Masters in Science Folic Acid Deficiency as a cause for Cerebral Vascular Thrombosis.

 

Graduate Chemistry Thesis

1995                Raul Trejo. Faculty of Chemistry. UNAM. Activated platelet rich

                   plasma supernatant for treatment of  diabetic ulcers.

  • Jessica Cuevas Manzo. QFB. Faculty of Bioanalysis. Universidad

Veracruzana. Activated Protein C in prothrombotic assays for the Clinical

Laboratory.

1998           Guadalupe Montiel. Faculty of Chemestry, UNAM.Prevalence   of Factor V Leiden in Public Hospitals, Mestizo Population.

  • Carlos Virgen. Universidad Veracruzana. Coagulation Parameters in

Lupus Patients

2016           Mara Nuñez. Instituto Nacional de Pediatría. (will finish in 2018)

 

Fellowship

1995           Carlos Rosillo. INCMNSZ. Lack of APCR and factor V Leiden Mutation as a causative Factor for Splacnic Vein Thrombosis.

 

 

Board Certification in Mexico

Internal Medicine

Hematology

 

Professional Memberships

ASH

ASCO

CLAHT (Latin American Group on Hemostasis and Thrombosis)

AMEH   (Asociación Mexicana para el Estudio de la Hematología)

HTRS

Anticoagulation Forum

THSNA

 

Joural Ad-Hoc Reviewer and Others

1995-     Rev. Invest.Clin.and Archives of Medical Research

1995 –    Scientific Committee Member. Premios Marcos y Cela Maus

for Masters and PHD Thesis in Medicine and SciencesUNAM

2001       Consultive Committee for the ISTH, Paris 2001

2012-     Applied Thrombosis and Haemostasis

2015 –    Molecular Cáncer

 

Honors and Awards

Second Place Generation 1979-85. Faculty of Medicine. UNAM

  • Chief Resident. Department of Haematology Oncologly. New.York Hospital. Cornell Medical Center.

1992-1994   Susan Murphy Fellow. Cornell Medical Center.

 

Dr. Luis Sanchez Medal Award.  Awarded by the Asociación Mexicana de Hematología

  • First Place for clinical research article. (Jury from Chile)
  • Third Place for basic research article (Jury from Argentina)

2016    Third Place for basic research article   (Jury from Venezuela)

 

Languages

Spanish, English. Read French, Italian, Idish.

 

Bibliography

 

  1. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahé I, Wilts IT, Twint DC, Porreca E, Arrieta O, Stépanian A, Smit K, De Tursi M, Bleker SM, Bossuyt PM, Nieuwland R, Kamphuisen, PW, Büller HR. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study Haematologica. 2017 Sep;102(9):1494-1501.
  2. Volkow P, Cesarman-Maus G, Garciadiego-Fossas P, Rojas-Marin E, Cornejo-Juárez P. Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma. AIDS Res Ther. 2017 May 30;14(1):30.
  3. Cesarman-Maus G, Ruiz-Argüelles GJ. News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians 2016 Guidelines. Curr Drug Metab. 2017;18(7):651-656.
  4. Fonseca R, Cesarman-Maus G, Braggio E.Personalizing the Use of Circulating Microparticle-Associated Tissue Factor as a Biomarker for Recurrent Thrombosis in Patients with Cancer. J Clin Oncol. 2017 Jul 1;35(19):2217-2218.Sánchez D, Pelayo R, Medina LA, Vadillo E, Sánchez R, Núñez L, Cesarman-Maus G, Sarmiento-Silva RE.Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.Viruses. 2015 Dec 23;8(1). pii: E3. doi: 10.3390/v8010003
  5. Cabrera-Fuentes HA, Alba-Alba C, Aragones J, Bernhagen J, Boisvert WA, Bøtker HE, Cesarman-Maus G, Fleming I, Garcia-Dorado D, Lecour S, Liehn E, Marber MS, Marina N, Mayr M, Perez-Mendez O, Miura T, Ruiz-Meana M, Salinas-Estefanon EM, Ong SB, Schnittler HJ, Sanchez-Vega JT, Sumoza-Toledo A, Vogel CW, Yarullina D, Yellon DM, Preissner KT, Hausenloy DJ. Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside. Basic Res Cardiol. 2016 Jan;111(1):7. doi: 10.1007/s00395-015-0527-0. Epub 2015 Dec 14.
  6. Meillón-García LA, Hernández-Zamora E, Montiel-Manzano G, Zavala-Hernández C, Ramírez-San Juan E, Cesarman-Maus G, Reyes-Maldonado E. Anticoagulant proteins in a population of Mexican mestizo donors. Ann Vasc Surg. 2015 Feb;29(2):222-6. doi: 10.1016/j.avsg.2014.09.023. Epub 2014 Nov 24.
  7. Cesarman-Maus G, Eteban Braggio, Carmen Lome-Maldonado, Ana Lilia Gómez-Leyte, Rafael Fonseca. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thrombosis Research 2014 133 (4), 606–609
  8. Cesarman-Maus G, Meillón L, Volkow P, Vargas-Ruiz AG, Cornejo P, López-Navarro O, Moreno MC, Coronel O, García-Fernandez L, Ochoa-Carrillo FJ, Siñani M, Baz P, Izaguirre R. Tratamiento de Cáncer y Trombosis: enfoque práctico. Rev Invest Clin. 2013 Mar-Apr;65(2):174-82.
  9. Cesarman-Maus G, Villa R, Peter Kubisz, Monica Gonzalez-Ramirez, G. El síndrome de Plaquetas Pegajosas.(SPP) Revista  de Hematología. 2013; 14 149-153
  10. Cesarman-Maus G, Eteban Braggio, Rafael Fonseca. Tissue factor and hematological neoplasias. Blood 2012, April 13 Re: Blood-2011-06-317685,
  11. Hedhli N, Falcone D, Huang B, Cesarman-Maus G. The Annexin A2/S100A10 System in health and disease: emerging paradigms. J. Biomed and Biotechnol 2012, (406273) pp:1-13
  12. Gabriela Cesarman-Maus, Esteban Braggio, Hector Maldonado, Rafael Fonseca. Absence of tissue factor expression by neoplatic plasma cells in multiple myeloma. Leukemia 2012, doi:10.1038/leu.2012.43  pag 1-4
  13. Gabriela Cesarman-Maus Esteban Braggio, Rafael Fonseca. Thrombosis in multiple myeloma. Hematology 2012. Vol 17, (suppl 1) pp. S1, S177 p.p 1-3
  14. Gabriela Cesarman-Maus. Myths and reality of Sticky platelet Syndrome.  Rev Hematol Mex 2011; 12(2): 55-56.
  15. Gabriela Cesarman-Maus MD, PhD, Carlos Cantú-Brito MD, PhD, Fernando Barinagarrementeria MD, Rosario Villa, Elba Reyes PhD, Jorge Sanchez-Guerrero MD, Katherine A Hajjar MD, Ethel Garcia Latorre PhD.  Autoantibodies against the Fibrinolytic Receptor, Annexin A2, in Cerebral Venous Thrombosis. Stoke. Adoi: 10.1161/Stroke AHA.110.592121 Feb 2011, 501-503.
  16. Escudero PM, y cols incluyendo Cesarman-Maus G. Parámetros de práctica clínica basados en evidencia en tromboprofilaxis. Trombosis y Cáncer. GAMO 2009, 08 (sup 4).
  17. Cesarman-Maus G, Rios-Luna P, Deora-Kumar A et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood, 2006 Jun 1;107(11):4375-82.
  18. Cesarman-Maus G, Hajjar KA. Annexin checks in – Response to Waisman. Br.J Haematol. 2005 Nov;131(4)
  19. Cesarman-Maus G. Hajjar K. Molecular Mechanisms of Fibrinolysis. Br.J.Haematol 2005 May;129(3):307-21
  20. Cesarman G. The Consular Program for Mexican Communities Abroad as a Source of Outreach for Health Workers. J Transcult Nurs 2003 14: 272-275.
  21. Montiel-Manzano G, de la Pena-Diaz A, Majluf-Cruz A, Cesarman-Maus G, Corona-de la Pena N, Cruz-Cruz D, Gaminio E, Martinez-Murillo C, Mayagoitia T, Miranda-Peralta E, Poblete T, Quintana-Martinez S, Ramirez Razo D, Ruiz de Chavez-Ochoa A, Reyes-Nunez VA, Salazar R, Vicencio-Santiago GV, Villa R. Evaluación Nacional del diagnóstico de la resistencia a la proteína C activada Rev Invest Clin. 2003 May-Jun;55(3):358-69.
  22. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C, Fanghanel-Salmon G, Gallegos-Martinez J, Gomez-Diaz RA, Salinas-Orozco S, Chavira-Lopez IJ, Sanchez-Reyes L, Torres-Acosta EM, Tamez R, Lopez A, Guillen LE, Cesarman G. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution. Metabolism. 2002 Jan;51(1):44-51.
  23. Cesarman.G Anti-Annexin antibodies and Antiphospholipid / cofactor Syndrome. Memorias del XVII Congreso CLAHT. 2002,
  24. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA.. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999 Apr 1;340(13):994- 1001
  25. Raffi S, Coleman M, Kaufmann T, Cesarman G, Papish SW, Bernhart B, Gaynor M, Reisman AM. CODBLAM IV chemotherapy for large cell lymphoma: sequential use of infusional vincristine and bleomycin and “high dose” consolidation. Am J Clin Oncol 1997 Feb;20(1):90-6
  26. Rojas G, Alberu J, Bordes-Aznar J, Quintanilla-Martinez L, Lome-Maldonado MC, Cesarman G, Angeles-Angeles A, Correa-Rotter Clinical and pathological characterization of posttransplantation lymphoproliferative disorders in kidney transplant recipients: single institution experience. R. Transplant Proc 1996 Dec;28(6):3317-20
  27. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA dependent plasminogen activation. J Biol Chem 1994 Aug 19;269(33):21198-203
  28. Cesarman G, Cesarman E, Lagos G. Prevention and treatment of traveler’s diarrhea. N Engl J Med 1993 Nov
  29. Herrera MF, Lozano-Salazar RR, Bezaury P, Cesarman G, Hernandez G, Sanchez SA, Velazquez A, Lopez-Karpovitch X. Laparoscopic splenectomy in autoimmune thrombocytopenic purpura. Rev Invest Clin. 1998 Mar-Apr;50(2):127-32. Spanish.
  30. Cesarman G. Agentes Fibrinolíticos. Mecanismos de Acción, Beneficios y Desventajas. Programa Educativo AMEH, 1996
  31. Cesarman G. Enfermedad de Von Willebrand. Programa Educativo AMEH, 1996
  32. Cesarman G. Update on the Fibrinolytic, protein C and S Systems. Revista de Investigación Clínica. 1995 April 47 (1): 226-31 Spanish
  33. Rao PH, Cesarman G, Coleman M, Acaron S, Verma RS.  Cytogenetic evidence for extramedullary   blast crisis with t(8;13),(q11;p11) in chronic myelomonocytic leukemia.  Acta Haematol 1992;88(4):201-04
  34. Sanchez-Guerrero J, Cesarman G, Alarcon-Segovia D. Massive pulmonary hemorrhage in mixed connective tissue diseases. J Rheumatol 1989 Aug;16(8):1132-4
  35. Guevara L, Cesarman G. Case Record. A 30-year-old woman with diabetes mellitus, generalized cutaneous hyperpigmentation and congestive heart failure. Rev Invest Clin 1986 Oct-Dec;38(4):429-33
  36. Cesarman. G. Angeles Angeles A. Pathological reclassification of non-Hodgkin´s lymphomas with the New Working Formulation. A retrospective review of clinical characteristics and outcomes.  Archivos UNAM  marzo1986.
  37. A M Silvia G Cesarman, I F Veja, L Mijares , A Cacho, M Pérez. Cáncer se vejiga avanzado” Advanced Bladder Cancer. Gamo Vol.5 Núm. 6 nov-dic 2006 pag.201 -204
  38. Cesarman-Maus Gabriela “Actualidades en los Sistemas Fibrinolitico y de Proteinas C y S.  La Revista de Investigación Cientifica. Suplemento 1 Vol. 47 Abril, 1995, pag. 16-19

 

 

Chapters in Books.

  1. Cesarman G. “Linfomas gastrointestinales primarios” Bandera J, Cañedo S, Olivera M y Schmulson M, Eds. Masson. Progresos en gastroenterologia.1a edicion 2001.pp143/150.

 

  1. Alberu J, Cesarman G et al. Clasificación clínica e histología de lesiones linfoproliferativas post-transplante. J. Alberú. L Soto Eds. Enfermedades Infecciosas en receptores de transplantes. Mc Graw Hill Interamericana, 1998.

 

  1. Cesarman G, Montiel-Manzano G. Anticoagulante Lupico. Manual de Laboratorio Clinico, 2005 .

 

  1. Kleinjan A, Bossuyt PM, Cesarman-Maus G et al. Prediction of venous thromboembolism in cancer patients by tissue factor dependent microparticle coagulant activity, biomarkers and clinical score. Eds. Ankie Kleinjan Venous Thrombosis in Cancer Patients. Prediction, Diagnosis and Management. 2013. Cap 7. pp 85-95
  2. Cesarman G, Izaquirre R, Meillón L, y cols. Oncoguías INCAN 2011. Guías de Cáncer y Trombosis.

6.Silvia Rivas, Cesarman G y cols. Oncoguías INCAN 2011. Guías de Linfomas.